2010 Guidelines Part 12: Cardiac Arrest in Special Situations: Writing Group Disclosures

Writing Group Member Employment Research Grant Other Research Support Speakers’ Bureau/ Honoraria Ownership Interest Consultant/ Advisory Board Other
Terry L. Vanden Hoek The University of Chicago-Associate Professor *Vanden Hoek, Principal Investigator, Department of Defense, Office of Naval Research, “Proteomic Development of Molecular
Vital Signs: Mapping a Mitochondrial Injury Severity Score to Triage and Guide Resuscitation of Hemorrhagic Shock.” Research
grant awarded to the University of Chicago
None None None None None
Laurie J. Morrison St. Michaels Clinician scientist None None None None None None
Michael Shuster Self-employed–emergency physician None None None None None None
Michael Donnino Harvard Medical Faculty Physicians–Physician Corticosteroids in Post-arrest Shock (American Heart Association, Scientist Development Grant); Thiamine as a Metabolic Resuscitator
in Septic Shock (NIH pending); *Statins in Sepsis (Eleanor Shore) Clinical Correlates to Influenza Genome (NIH); Thiamine Deficiency in Critically Ill (Harvard
Medical School/NIH); Thiamine for Congestive Heart Failure (Baystate Incubator Fund-NON-industry, academic hospital funding)
None None None None None
Elizabeth Sinz Penn State Hershey Medical Center–Professor of Anesthesiology and Neurosurgery; AHA–Associate Science Editor None None None None None None
Eric J. Lavonas Rocky Mountain Poison & Drug Center; (RMPDC) Denver, Colo. Associate Director RMPDC performed research related to hydroxocobalamin prior to its licensure in the United States. This occurred prior to my
arrival at RMPDC. RMPDC-DH performed work related to the development of hydroxocobalamin (CyanoKit, Dey LP) as a cyanide antidote.
Various projects were completed in 2001, 2005, and 2006. Some of the sponsors of this research (EMD; Merck KGA) either no
longer exist or no longer have an interest in hydroxocobalamin. I was not involved in this research, which was performed long
before my arrival. RMPDC-DH does not have any current or pending hydroxocobalamin-related projects. Neither I nor any other
DHHA employee derives personal financial benefit from these relationships. I don’t get a bonus of any sort. My salary is supported
by general institutional funds and an unrelated research endowment. Also, my performance evaluation is not related the performance
of any of these contracts. My role: PI on one portion of the project, collaborator on the rest 2008–2009 (ongoing)
None None None None None
Farida M. Jeejeebhoy Self employed cardiologist, affiliate with University Health Network/Mt Sinai and University of Toronto None None None None None None
Andrea Gabrielli University of Florida–Professor of Anesthesiology and Surgery NIH-Biomarkers in Traumatic Brain Injury None None None None None
  • This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts
    of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and
    submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period,
    or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity,
    or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less
    than “significant” under the preceding definition.

  • * Modest.

  • Significant.